MedTrace Logo

Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II

NCT06615102 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1022

Last updated 2025-07-18

No results posted yet for this study

Summary

The study intervention focuses on exploring the use of angiotensin II as a primary vasopressor compared to norepinephrine in cardiac surgery patients to investigate whether angiotensin II can reduce the occurrence of moderate/severe acute kidney injury (AKI). Despite its potential, as suggested by trials involving surgical patients, there is currently no human data confirming its effectiveness in preventing moderate/severe AKI in this context. The intervention aims to address this gap by evaluating angiotensin II's impact compared to norepinephrine.

Conditions

  • Cardiac Surgery
  • Vasoplegia

Interventions

DRUG

Angiotensin II

Intravenous infusion through a central line according to the patient's situation. Once an infusion is established, the dose will be titrated as frequently as every 5 minutes, as needed, depending on the patient's condition and target MAP.

DRUG

Noradrenalin

Intravenous infusion through a central line according to the patient's situation. Once an infusion is established, the dose will be titrated as frequently as every 5 minutes, as needed, depending on the patient's condition and target MAP.

Sponsors & Collaborators

  • German Research Foundation

    collaborator OTHER

  • Universität Münster

    lead OTHER

Principal Investigators

  • Alexander Zarbock, MD · University Hospital Muenster, Dept. of Anesthesiology, Intensive Care Medicine and Pain Therapy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2027-01-31
Completion
2027-04-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06615102 on ClinicalTrials.gov